Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced
today that John Higgins, President and Chief Executive Officer of
Ligand, will present at the Biotech Showcase 2012 Conference on Tuesday,
January 10, 2012 at 5:00 p.m. Pacific (8:00 p.m. Eastern Time). The
conference takes place at the Parc 55 Wyndham hotel in San Francisco.
A live webcast of the presentation will be available on the Company’s
website www.ligand.com.
A replay of the presentation will be archived on the site for 30 days.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company with a business model that is
based upon the concept of developing or acquiring royalty revenue
generating assets and coupling them to a lean corporate cost structure.
Ligand’s goal is to produce a bottom line that supports a sustainably
profitable business. By diversifying the portfolio of assets across
numerous technology types, therapeutic areas, drug targets, and industry
partners, we offer investors an opportunity to invest in the
increasingly complicated and unpredictable pharmaceutical industry. In
comparison to its peers, we believe Ligand has assembled one of the
largest and most diversified asset portfolios in the industry with the
potential to generate revenue in the future. These therapies address the
unmet medical needs of patients for a broad spectrum of diseases
including hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia,
diabetes, anemia, asthma, rheumatoid arthritis and osteoporosis.
Ligand’s Captisol platform technology is a patent protected, chemically
modified cyclodextrin with a structure designed to optimize the
solubility and stability of drugs. Ligand has established multiple
alliances with the world's leading pharmaceutical companies including
GlaxoSmithKline, Merck, Pfizer, Eli Lilly & Company, Baxter
International, Bristol-Myers Squibb, Celgene, Onyx Pharmaceuticals,
Lundbeck Inc., The Medicines Company, Curis, Inc. and Rib-X
Pharmaceuticals. Please visit www.captisol.com
for more information on Captisol. For more information on Ligand, please
visit www.ligand.com.
Follow Ligand on Twitter @Ligand_LGND.
